Cite
Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine (ERVEBO®) in African clinical trial participants by age, sex, and baseline GP-ELISA titer: A post hoc analysis of three Phase 2/3 trials.
MLA
Simon, Jakub K., et al. “Immunogenicity of RVSVΔG-ZEBOV-GP Ebola Vaccine (ERVEBO®) in African Clinical Trial Participants by Age, Sex, and Baseline GP-ELISA Titer: A Post Hoc Analysis of Three Phase 2/3 Trials.” Vaccine, vol. 40, no. 46, Nov. 2022, pp. 6599–606. EBSCOhost, https://doi.org/10.1016/j.vaccine.2022.09.037.
APA
Simon, J. K., Kennedy, S. B., Mahon, B. E., Dubey, S. A., Grant-Klein, R. J., Liu, K., Hartzel, J., Coller, B.-A. G., Welebob, C., Hanson, M. E., & Grais, R. F. (2022). Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine (ERVEBO®) in African clinical trial participants by age, sex, and baseline GP-ELISA titer: A post hoc analysis of three Phase 2/3 trials. Vaccine, 40(46), 6599–6606. https://doi.org/10.1016/j.vaccine.2022.09.037
Chicago
Simon, Jakub K., Stephen B. Kennedy, Barbara E. Mahon, Sheri A. Dubey, Rebecca J. Grant-Klein, Ken Liu, Jonathan Hartzel, et al. 2022. “Immunogenicity of RVSVΔG-ZEBOV-GP Ebola Vaccine (ERVEBO®) in African Clinical Trial Participants by Age, Sex, and Baseline GP-ELISA Titer: A Post Hoc Analysis of Three Phase 2/3 Trials.” Vaccine 40 (46): 6599–6606. doi:10.1016/j.vaccine.2022.09.037.